News | March 14, 2022
Applications for PLI in bulk drugs extended till March 31st 2022
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Domestic business was up 41.9% YoY and 27.7% QoQ
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The govt has rolled out three schemes for promoting the manufacture of API
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
